Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-18T15:45:37.325Z Has data issue: false hasContentIssue false
  • English
  • Français

Antenatal betamethasone increases vascular reactivity to endothelin-1 by upregulation of CD38/cADPR signaling

Published online by Cambridge University Press:  10 January 2014

J.-H. Lee ,
J. Zhang ,
G. A. Massmann  and
J. P. Figueroa
J.-H. Lee
Affiliation:
Department of Obstetrics and Gynecology, Center for Research in Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, NC, USA Department of Obstetrics and Gynecology, Chonbuk National University Medical School, Jeonju, South Korea
J. Zhang
Affiliation:
Department of Obstetrics and Gynecology, Center for Research in Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
G. A. Massmann
Affiliation:
Department of Obstetrics and Gynecology, Center for Research in Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
J. P. Figueroa*
Affiliation:
Department of Obstetrics and Gynecology, Center for Research in Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
*
*Address for correspondence: Jorge P. Figueroa, Department of Obstetrics and Gynecology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. (Email figueroa@wakehealth.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Antenatal steroid administration is associated with hypertension in adult life; however, the mechanisms underlying this phenomenon are unclear. The aim of this study was to further characterize the effects of antenatal glucocorticoid exposure on the endothelin (ET-1) system, specifically to ascertain the role of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine receptor pathway in the increased sensitivity to ET-1 observed in the offspring exposed to antenatal glucocorticoids. Pregnant sheep were randomly treated with betamethasone (Beta; 0.17 mg/kg) or vehicle at 80 and 81 days of gestation. In adults, we studied endothelium-denuded arterial segments of the brachial arteries. ET-1-induced vasoconstriction was significantly higher in the arteries from Beta sheep (F=3.5, P<0.05). Inhibition of ADP-ribosyl cyclase with 2-2'-dihydroxy-azobenzene significantly decreased the ET-1-induced contraction in Beta but not in vehicle-treated sheep. Nicotinamide attenuated ET-1 contraction in both, but it was significantly more pronounced in the Beta-treated sheep. No significant differences were observed following KCl-induced (6.25–75 mM) contraction. Nicotinamide (10 mM) significantly attenuated the KCl-induced vasoconstriction in both groups. In KCl (62.5 mM)-constricted arteries, the effect of nicotinamide (NIC) was significantly greater in the vehicle-treated sheep (50% relaxation v. 40% relaxation; t=2.2, P<0.05). In contrast, the sodium nitroprusside (SNP) relaxation was not statistically different. An additive effect was observed when NIC and SNP were used in combination and it was also more pronounced in vehicle-treated sheep. We conclude that the increased response to ET-1 is mediated by activation of the CD38/cADPR signaling pathway. Further studies are required to identify the effectors downstream from cADPR affected by exposure to antenatal steroids.

Keywords

animallarge animalsmolecular/cellular
Type
Original Article
Information
Journal of Developmental Origins of Health and Disease , Volume 5 , Issue 1 , February 2014 , pp. 56 - 62
Copyright
© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Barker, DJ. Fetal origins of coronary heart disease. Br Heart J. 1993; 69, 195–196.Google Scholar
2. Figueroa, JP, Rose, JC, Massmann, GA, Zhang, J, Acuna, G. Alterations in fetal kidney development and elevations in arterial blood pressure in young adult sheep after clinical doses of antenatal glucocorticoids. Pediatr Res. 2005; 58, 510–515.Google Scholar
3. Dodic, M, May, CN, Wintour, EM, Coghlan, JP. An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep. Clin Sci. 1998; 94, 149–155.CrossRefGoogle ScholarPubMed
4. Doyle, LW, Ford, GW, Rickards, AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 2000; 106, E2.Google Scholar
5. Adair, L, Dahly, D. Developmental determinants of blood pressure in adults. Annu Rev Nutr. 2005; 25, 407–434.CrossRefGoogle ScholarPubMed
6. Kutzler, MA, Molnar, J, Schlafer, DH, et al. Maternal dexamethasone increases endothelin-1 sensitivity and endothelin a receptor expression in ovine foetal placental arteries. Placenta. 2003; 24, 392–402.CrossRefGoogle ScholarPubMed
7. Molnar, J, Howe, DC, Nijland, MJ, Nathanielsz, PW. Prenatal dexamethasone leads to both endothelial dysfunction and vasodilatory compensation in sheep. J Physiol. 2003; 547(Pt 1), 61–66.Google Scholar
8. Pulgar, VM, Figueroa, JP. Antenatal betamethasone administration has a dual effect on adult sheep vascular reactivity. Pediatr Res. 2006; 60, 705–710.Google Scholar
9. Lee, JH, Zhang, J, Flores, L, et al. Antenatal betamethasone has a sex-dependent effect on the in vivo response to endothelin in adult sheep. Am J Physiol Regul Integr Comp Physiol. 2013; 304, R581–R587.Google Scholar
10. Bai, N, Lee, HC, Laher, I. Emerging role of cyclic ADP-ribose (cADPR) in smooth muscle. Pharmacol Ther. 2005; 105, 189–207.CrossRefGoogle ScholarPubMed
11. Yu, JZ, Zhang, DX, Zou, AP, Campbell, WB, Li, PL. Nitric oxide inhibits Ca(2+) mobilization through cADP-ribose signaling in coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000; 279, H873–H881.Google Scholar
12. Zhang, AY, Li, PL. Vascular physiology of a Ca2+ mobilizing second messenger – cyclic ADP-ribose. J Cell Mol Med. 2006; 10, 407–422.Google Scholar
13. Galione, A. Cyclic ADP-ribose: a new way to control calcium. Science. 1993; 259, 325–326.CrossRefGoogle ScholarPubMed
14. Lee, HC, Walseth, TF, Bratt, GT, Hayes, RN, Clapper, DL. Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. J Biol Chem. 1989; 264, 1608–1615.CrossRefGoogle ScholarPubMed
15. Aarhus, R, Graeff, RM, Dickey, DM, Walseth, TF, Lee, HC. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995; 270, 30,327–30,333.Google Scholar
16. Lee, HC. Potentiation of calcium- and caffeine-induced calcium release by cyclic ADP-ribose. J Biol Chem. 1993; 268, 293–299.Google Scholar
17. Giulumian, AD, Meszaros, LG, Fuchs, LC. Endothelin-1-induced contraction of mesenteric small arteries is mediated by ryanodine receptor Ca2+ channels and cyclic ADP-ribose. J Cardiovasc Pharmacol. 2000; 36, 758–763.Google Scholar
18. Barone, F, Genazzani, AA, Conti, A, et al. A pivotal role for cADPR-mediated Ca2+ signaling: regulation of endothelin-induced contraction in peritubular smooth muscle cells. FASEB J. 2002; 16, 697–705.Google Scholar
19. Thai, TL, Arendshorst, WJ. ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo. Am J Physiol Renal Physiol. 2008; 295, F360–F368.Google Scholar
20. Schiffrin, EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005; 43, 19–29.Google Scholar
21. Orleans-Juste, P, Labonte, J, Bkaily, G, et al. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther. 2002; 95, 221–238.CrossRefGoogle ScholarPubMed
22. Zalk, R, Lehnart, SE, Marks, AR. Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem. 2007; 76, 367–385.Google Scholar
23. Lee, HC. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Ann Rev Pharmacol Toxicol. 2001; 41, 317–345.Google Scholar
24. Sauve, AA, Munshi, C, Lee, HC, Schramm, VL. The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries. Biochemistry. 1998; 37, 13,239–13,249.CrossRefGoogle ScholarPubMed
25. Malavasi, F, Deaglio, S, Funaro, A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88, 841–886.Google Scholar
26. Gul, R, Park, JH, Kim, SY, et al. Inhibition of ADP-ribosyl cyclase attenuates angiotensin II-induced cardiac hypertrophy. Cardiovasc Res. 2009; 81, 582–591.CrossRefGoogle ScholarPubMed
27. de Toledo, FG, Cheng, J, Liang, M, Chini, EN, Dousa, TP. ADP-ribosyl cyclase in rat vascular smooth muscle cells: properties and regulation. Circ Res. 2000; 86, 1153–1159.Google Scholar
28. Laporte, R, Hui, A, Laher, I. Pharmacological modulation of sarcoplasmic reticulum function in smooth muscle. Pharmacol Rev. 2004; 56, 439–513.Google Scholar
29. Zhang, DX, Harrison, MD, Li, PL. Calcium-induced calcium release and cyclic ADP-ribose-mediated signaling in the myocytes from small coronary arteries. Microvasc Res. 2002; 64, 339–348.Google Scholar
30. Geiger, J, Zou, AP, Campbell, WB, Li, PL. Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension. 2000; 35, 397–402.Google Scholar
31. Kuemmerle, JF, Makhlouf, GM. Agonist-stimulated cyclic ADP ribose. Endogenous modulator of Ca(2+)-induced Ca2+ release in intestinal longitudinal muscle. J Biol Chem. 1995; 270, 25,488–25,494.CrossRefGoogle ScholarPubMed
32. Li, PL, Zou, AP, Campbell, WB. Regulation of KCa-channel activity by cyclic ADP-ribose and ADP-ribose in coronary arterial smooth muscle. Am J Physiol – Heart Circ Physiol. 1998; 275, H1002–H1010.CrossRefGoogle ScholarPubMed
33. Fellner, SK, Arendshorst, WJ. Voltage-gated Ca2+ entry and ryanodine receptor Ca2+-induced Ca2+ release in preglomerular arterioles. Am J Physiol – Renal Physiol. 2007; 292, F1568–F1572.Google Scholar
34. Archer, SL, Huang, JMC, Hampl, V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994; 91, 7583–7587.Google Scholar
35. Li, N, Zou, AP, Ge, ZD, Campbell, WB, Li, PL. Effect of nitric oxide on calcium-induced calcium release in coronary arterial smooth muscle. Gen Pharmacol. 2000; 35, 37–45.CrossRefGoogle ScholarPubMed
36. Bolotina, VM, Najibi, S, Palacino, JJ, Pagano, PJ, Cohen, RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994; 368, 850–853.CrossRefGoogle ScholarPubMed
37. Bielefeldt, K, Sharma, RV, Whiteis, C, Yedidag, E, Abboud, FM. Tacrolimus (FK506) modulates calcium release and contractility of intestinal smooth muscle. Cell Calcium. 1997; 22, 507–514.Google Scholar
38. Zhang, F, Jin, S, Yi, F, et al. Local production of O2- by NAD(P)H oxidase in the sarcoplasmic reticulum of coronary arterial myocytes: cADPR-mediated Ca2+ regulation. Cell Signal. 2008; 20, 637–644.Google Scholar
39. Xu, M, Zhang, Y, Xia, M, et al. NAD(P)H oxidase-dependent intracellular and extracellular OO2∙- production in coronary arterial myocytes from CD38 knockout mice. Free Rad Biol Med. 2012; 52, 357–365.Google Scholar
40. Noguchi, N, Takasawa, S, Nata, K, et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. J Biol Chem. 1997; 272, 3133–3136.CrossRefGoogle ScholarPubMed